What Is Bemotrizinol? New FDA-Proposed Sunscreen Ingredient

Everything to Know About the New FDA-Proposed Sunscreen Ingredient

If you’ve been keeping up with skincare news, you may have seen headlines about a new Food and Drug Administration (FDA) sunscreen ingredient making waves: bemotrizinol. It’s the first new sunscreen ingredient proposed for approval in the U.S., in roughly 25 years, and it’s already generating buzz for its ultraviolet A (UVA) protection. 

So what is bemotrizinol, why does it matter, and should you add it to your routine? Dr. Alexa Stecker, DO, FAOCD, breaks it down.

What Is Bemotrizinol?

In plain terms, bemotrizinol is a sunscreen ingredient that was recently proposed for FDA approval in the United States. According to Dr. Stecker, it offers excellent protection against the ultraviolet A (UVA) spectrum and that’s a big deal.

To understand why, it helps to know the difference between UVA and ultraviolet B (UVB) rays. 

• UVB rays are short-wave ultraviolet rays that primarily damage the skin’s surface layers and are primarily responsible for sunburn.
• UVA rays penetrate deeper into the skin and are associated with premature aging, including wrinkles, dark spots, and loss of elasticity over time. 
• Both types of ultraviolet radiation can contribute to skin cancer, which is why broad-spectrum formulas—protection from both UVA and UVB rays—is so important.

Bemotrizinol isn’t new to the world. It’s been approved and used in Europe and other countries for more than 20 years. The FDA’s recent approval makes it new to the United States.

Why UVA Protection Matters

UVA rays account for up to 95% of the UV radiation reaching Earth, are present year-round and can cut through clouds and glass. Because UVA rays penetrate deeper into the skin and mutate skin cells, UVA coverage is especially important for patients who have a history of skin cancer. 

Choosing a broad-spectrum sunscreen that covers both UVA and UVB is essential, and according to Dr. Stecker, this is where many current U.S. sunscreen options fall short. Bemotrizinol offers excellent UVA protection in a category where the gap is noticeable.

Chemical vs. Mineral Sunscreen, and Where Bemotrizinol Fits

No White Cast, No Stabilizers Needed

One practical perk: bemotrizinol doesn’t tend to leave a white cast. That chalky residue is typically associated with mineral blockers like zinc oxide and titanium dioxide, which physically block all light rays and tend to sit visibly on the skin. In European formulations, “[bemotrizinol] has not left as significant of any white cast,” Dr. Strecker says.

That said, her recommendation is to look for sunscreens that combine both mineral and chemical protection, something with bemotrizinol alongside an ingredient like zinc oxide or titanium dioxide, for the most comprehensive coverage. 

Sunscreen formulations have advanced significantly, and many tinted options now offer excellent protection with minimal cosmetic downsides. Tinted sunscreens have an added benefit, too: they contain iron oxide, which helps protect against visible light as well.

There’s also a formulation advantage worth noting. Traditional chemical sunscreen ingredients used in the U.S., like oxybenzone, require stabilizers because they degrade with sun exposure, and that degradation process is part of how they end up being absorbed systemically. Bemotrizinol doesn’t need those stabilizers and can function effectively on its own.

The FDA Angle: Why This Is a Big Deal

The FDA proposing bemotrizinol for the approved sunscreen ingredients list is notable because it has been 25 years since a new ingredient was added. The proposal allows concentrations up to 6%.

The FDA has very strict guidelines for approving new sunscreen ingredients in the U.S. Given these strict standards, Dr. Stecker notes that this approval matters clinically. The hope is that the approval encourages more people to use sunscreen consistently in the first place, since most people aren’t applying it as often or as generously as recommended (about a shot glass full, reapplied every two hours).

What About Patients Already Buying European Sunscreens?

Some patients have already started purchasing European or imported sunscreens specifically to access bemotrizinol ahead of its U.S. approval. Dr. Stecker’s take: that’s a reasonable approach for patients who are already doing it, and they can continue using those products.

That said, her general guidance leans toward what’s approved by the FDA. As bemotrizinol products roll out domestically, patients can consider switching to gain the additional UVA protection, particularly patients for whom that protection matters most.

Do You Need to Switch Right Away?

If you’re already using mineral or medical-grade sunscreen regularly and correctly, you don’t necessarily need to make any changes. 

“The very best sunscreen is whatever the patient is going to use consistently and appropriately,” Dr. Stecker says.

Her broader philosophy hasn’t changed: frequent reapplication, especially when outdoors, sweating, or swimming, combined with broad-spectrum coverage (ideally both chemical and mineral) and general sun avoidance during peak intensity remains the foundation of good sun protection.

If patients are looking for guidance and want the best possible protection, switching to something with bemotrizinol once it’s available is a good option. But if someone already has a sunscreen they like and use reliably, there’s no urgency to change.

Have questions about bemotrizinol or want to update your sunscreen routine? Book a consultation with the team at Apex Skin today.